{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:56:38Z","timestamp":1793332598714,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005187","name":"University of Athens","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005187","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The interval since the 2021 European Society of Cardiology (ESC) Guidelines and 2022 American Heart Association\/American College of Cardiology\/Heart Failure Society of America (AHA\/ACC\/HFSA) Guidelines publications has witnessed an unprecedented volume of evidence that substantially expands the therapeutic landscape across the entire ejection fraction (EF) spectrum. Major developments include the emergence of non-steroidal mineralocorticoid receptor antagonists and incretin-based therapies for heart failure (HF) with mildly reduced and preserved EF, the validation of rapid guideline-directed medical therapy optimization strategies in acute HF, and new evidence supporting digitalis glycosides in HF patients with reduced EF. Device-based care has evolved with transcatheter edge-to-edge repair for valvular heart disease. These data are likely to reshape contemporary clinical practice.<\/jats:p>","DOI":"10.1007\/s10741-026-10609-3","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:10:18Z","timestamp":1773213018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Heart failure evidence update 2026"],"prefix":"10.1007","volume":"31","author":[{"given":"Sotiria","family":"Liori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J.","family":"Kapelios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"16","key":"10609_CR1","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS et al (2024) Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 391(16):1475\u20131485 doi:10.1056\/NEJMoa2407107 PubMed PMID: 39225278","journal-title":"N Engl J Med"},{"issue":"5","key":"10609_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V et al (2025) Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 392(5):427\u2013437 doi:10.1056\/NEJMoa2410027 PubMed PMID: 39555826","journal-title":"N Engl J Med"},{"issue":"12","key":"10609_CR3","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M et al (2023) Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med 389(12):1069\u20131084 doi:10.1056\/NEJMoa2306963 PubMed PMID: 37622681","journal-title":"N Engl J Med"},{"issue":"10","key":"10609_CR4","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.cjca.2025.07","volume":"41","author":"S Virani","year":"2025","unstructured":"Virani S, Zieroth S, Aleksova N, Anderson K, Clarke B, Ducharme A et al (2025) Canadian Cardiovascular Society\/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF\u2009>\u200940%). Can J Cardiol 41(10):1857\u20131874. https:\/\/doi.org\/10.1016\/j.cjca.2025.07.027 PubMed PMID: 41110921","journal-title":"Can J Cardiol"},{"issue":"8","key":"10609_CR5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1253\/circj","volume":"89","author":"T Kitai","year":"2025","unstructured":"Kitai T, Kohsaka S, Kato T, Kato E, Sato K, Teramoto K et al (2025) JCS\/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure. Circ J Off J Jpn Circ Soc 89(8):1278\u20131444. https:\/\/doi.org\/10.1253\/circj.CJ-25-0002 PubMed PMID: 40159241","journal-title":"Circ J Off J Jpn Circ Soc"},{"issue":"22","key":"10609_CR6","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa2300213","volume":"388","author":"GW Stone","year":"2023","unstructured":"Stone GW, Abraham WT, Lindenfeld J, Kar S, Grayburn PA, Lim DS et al (2023) Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. N Engl J Med 388(22):2037\u20132048 doi:10.1056\/NEJMoa2300213 PubMed PMID: 36876756","journal-title":"N Engl J Med"},{"issue":"8","key":"10609_CR7","doi-asserted-by":"publisher","first-page":"e012888","DOI":"10.1161\/CIRCINTERVENTIONS.122.012888","volume":"16","author":"RS von Bardeleben","year":"2023","unstructured":"von Bardeleben RS, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M et al (2023) Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic TRILUMINATE Trial. Circ Cardiovasc Interv 16(8):e012888. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.122.012888PubMed PMID: 37582170","journal-title":"Circ Cardiovasc Interv"},{"issue":"10","key":"10609_CR8","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","volume":"29","author":"JM ter Maaten","year":"2023","unstructured":"ter Maaten JM, Beldhuis IE, van der Meer P, Krikken JA, Postmus D, Coster JE et al (2023) Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nat Med 29(10):2625\u20132632. https:\/\/doi.org\/10.1038\/s41591-023-02532-z","journal-title":"Nat Med"},{"issue":"10","key":"10609_CR9","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/ejhf.3429","volume":"26","author":"E Meekers","year":"2024","unstructured":"Meekers E, Martens P, Dauw J, Gruwez H, Dhont S, Nijst P et al (2024) Nurse-led diuretic titration via a point-of-care urinary sodium sensor in patients with acute decompensated heart failure (EASY-HF): A single-centre, randomized, open-label study. Eur J Heart Fail 26(10):2129\u20132139. https:\/\/doi.org\/10.1002\/ejhf.3429PubMed PMID: 39140288","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10609_CR10","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.jacadv.2024.101250","volume":"3","author":"JA Jacobs","year":"2024","unstructured":"Jacobs JA, Carter SJ, Bullock G, Carey JR, Pan IZ, Kinsey MS et al (2024) Optimal Initial Intravenous Loop Diuretic Dosing in Acute Decompensated Heart Failure. JACC Adv 3(10):101250. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101250PubMed PMID: 39290819; PubMed Central PMCID: PMC11406012","journal-title":"JACC Adv"},{"issue":"9","key":"10609_CR11","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/ejhf.2985","volume":"25","author":"A Vazir","year":"2023","unstructured":"Vazir A, Kapelios CJ, Agaoglu E, Metra M, Lopatin Y, Seferovic P et al (2023) Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians. Eur J Heart Fail 25(9):1555\u20131570. https:\/\/doi.org\/10.1002\/ejhf.2985PubMed PMID: 37565377","journal-title":"Eur J Heart Fail"},{"issue":"14","key":"10609_CR12","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","volume":"83","author":"ZL Cox","year":"2024","unstructured":"Cox ZL, Collins SP, Hernandez GA, McRae AT, Davidson BT, Adams K et al (2024) Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. J Am Coll Cardiol 83(14):1295\u20131306. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.009PubMed PMID: 38569758","journal-title":"J Am Coll Cardiol"},{"issue":"31","key":"10609_CR13","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","volume":"44","author":"SE Yeoh","year":"2023","unstructured":"Yeoh SE, Osmanska J, Petrie MC, Brooksbank KJM, Clark AL, Docherty KF et al (2023) Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics. Eur Heart J 44(31):2966\u20132977. https:\/\/doi.org\/10.1093\/eurheartj\/ehad341PubMed PMID: 37210742; PubMed Central PMCID: PMC10424881","journal-title":"Eur Heart J"},{"issue":"1","key":"10609_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","volume":"44","author":"J Biegus","year":"2023","unstructured":"Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE et al (2023) Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J 44(1):41\u201350. https:\/\/doi.org\/10.1093\/eurheartj\/ehac530PubMed PMID: 36254693; PubMed Central PMCID: PMC9805406","journal-title":"Eur Heart J"},{"issue":"5","key":"10609_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1093\/eurheartj\/ehac689","volume":"44","author":"JC Trull\u00e0s","year":"2023","unstructured":"Trull\u00e0s JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, S\u00e1nchez-Marteles M, Conde-Martel A et al (2023) Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial. Eur Heart J 44(5):411\u2013421. https:\/\/doi.org\/10.1093\/eurheartj\/ehac689PubMed PMID: 36423214","journal-title":"Eur Heart J"},{"key":"10609_CR16","unstructured":"Rao VS, Cox ZL, Ivey-Miranda JB, Moreno-Villagomez J, Ramos-Mastache D, Maulion C et al (2025 Sep) Loop Diuretic Dose Intensification versus Adjuvant Thiazide for Diuretic Resistance in Acute Heart Failure: Mechanistic Randomized Controlled Trial. J Am Soc Nephrol JASN 12. 101681\/ASN.0000000887 PubMed PMID: 40938670"},{"issue":"13","key":"10609_CR17","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMoa2203094","volume":"387","author":"W Mullens","year":"2022","unstructured":"Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E et al (2022) Acetazolamide in Acute Decompensated Heart Failure with Volume Overload. N Engl J Med 387(13):1185\u20131195. https:\/\/doi.org\/10.1056\/NEJMoa2203094","journal-title":"N Engl J Med"},{"issue":"3","key":"10609_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jchf.2023","volume":"11","author":"SJ Greene","year":"2023","unstructured":"Greene SJ, Felker GM (2023) Considering Addition of Acetazolamide to Loop Diuretics as Treatment for Acute Heart Failure: ADVOR Reappraisal. JACC Heart Fail 11(3):365\u2013367. https:\/\/doi.org\/10.1016\/j.jchf.202301.011 PubMed PMID: 36889884","journal-title":"JACC Heart Fail"},{"issue":"22","key":"10609_CR19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/eurheartj\/ehad236","volume":"44","author":"P Martens","year":"2023","unstructured":"Martens P, Verbrugge FH, Dauw J, Nijst P, Meekers E, Augusto SN et al (2023) Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial. Eur Heart J 44(22):1995\u20132005. https:\/\/doi.org\/10.1093\/eurheartj\/ehad236PubMed PMID: 37138385","journal-title":"Eur Heart J"},{"issue":"7","key":"10609_CR20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/ejhf.2888","volume":"25","author":"M Metra","year":"2023","unstructured":"Metra M, Adamo M, Tomasoni D, Mebazaa A, Bayes-Genis A, Abdelhamid M et al (2023) Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC. Eur J Heart Fail 25(7):1115\u20131131. https:\/\/doi.org\/10.1002\/ejhf.2888PubMed PMID: 37448210","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10609_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","volume":"24","author":"TA McDonagh","year":"2022","unstructured":"Authors\/Task Force Members:, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A et al (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24(1):4\u2013131. https:\/\/doi.org\/10.1002\/ejhf.2333PubMed PMID: 35083827","journal-title":"Eur J Heart Fail"},{"issue":"10367","key":"10609_CR22","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(","volume":"400","author":"A Mebazaa","year":"2022","unstructured":"Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G et al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet Lond Engl 400(10367):1938\u20131952. https:\/\/doi.org\/10.1016\/S0140-6736(22)02076-1 PubMed PMID: 36356631","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"10609_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jacc.2024.04.055","volume":"84","author":"J Biegus","year":"2024","unstructured":"Biegus J, Mebazaa A, Davison B, Cotter G, Edwards C, \u010celutkien\u0117 J et al (2024) Effects of Rapid Uptitration of Neurohormonal Blockade on Effective, Sustainable Decongestion and Outcomes in STRONG-HF. J Am Coll Cardiol 84(4):323\u2013336. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.055PubMed PMID: 39019527","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10609_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jamacardio.2023.5318","volume":"9","author":"O Vardeny","year":"2024","unstructured":"Vardeny O, Desai AS, Jhund PS, Fang JC, Claggett B, de Boer RA et al (2024) Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction: A Post Hoc Analysis of the DELIVER Trial. JAMA Cardiol 9(3):283\u2013289. https:\/\/doi.org\/10.1001\/jamacardio.2023.5318PubMed PMID: 38265835; PubMed Central PMCID: PMC10809142","journal-title":"JAMA Cardiol"},{"issue":"10354","key":"10609_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(","volume":"400","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF et al (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet Lond Engl 400(10354):757\u2013767. https:\/\/doi.org\/10.1016\/S0140-6736(22)01429-5 PubMed PMID: 36041474","journal-title":"Lancet Lond Engl"},{"issue":"10254","key":"10609_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet Lond Engl 396(10254):819\u2013829. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9 PubMed PMID: 32877652","journal-title":"Lancet Lond Engl"},{"issue":"21","key":"10609_CR27","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","volume":"149","author":"AF Hernandez","year":"2024","unstructured":"Hernandez AF, Udell JA, Jones WS, Anker SD, Petrie MC, Harrington J et al (2024) Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation 149(21):1627\u20131638. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069217PubMed PMID: 38581389; PubMed Central PMCID: PMC11115458","journal-title":"Circulation"},{"issue":"2","key":"10609_CR28","doi-asserted-by":"publisher","first-page":"EVIDoa2300286","DOI":"10.1056\/EVIDoa2300286","volume":"3","author":"S James","year":"2024","unstructured":"James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N et al (2024) Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid 3(2):EVIDoa2300286. 101056\/EVIDoa2300286 PubMed PMID: 38320489","journal-title":"NEJM Evid"},{"issue":"10458","key":"10609_CR29","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS et al (2024) Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet Lond Engl 404(10458):1119\u20131131. https:\/\/doi.org\/10.1016\/S0140-6736(24)01733-1 PubMed PMID: 39232490","journal-title":"Lancet Lond Engl"},{"issue":"12","key":"10609_CR30","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","volume":"30","author":"M Vaduganathan","year":"2024","unstructured":"Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A et al (2024) Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med 30(12):3758\u20133764. https:\/\/doi.org\/10.1038\/s41591-024-03264-4PubMed PMID: 39218030; PubMed Central PMCID: PMC11645272","journal-title":"Nat Med"},{"issue":"23","key":"10609_CR31","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al (2020) Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"issue":"24","key":"10609_CR32","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P et al (2021) Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 385(24):2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"issue":"11","key":"10609_CR33","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/ejhf.3453","volume":"26","author":"LH Lund","year":"2024","unstructured":"Lund LH, James S, DeVore AD, Anstrom KJ, Fudim M, Aaronson KD et al (2024) The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design. Eur J Heart Fail 26(11):2453\u20132463. https:\/\/doi.org\/10.1002\/ejhf.3453PubMed PMID: 39282788; PubMed Central PMCID: PMC11659483","journal-title":"Eur J Heart Fail"},{"key":"10609_CR34","unstructured":"Edelmann UPD med F. Spironolactone in the Treatment of Heart Failure- a Double-blind, Randomized, Placebo-controlled, Parallel Group Interventional Phase III Study to Determine Efficacy and Safety of Spironolactone on the Composite Endpoint of Recurrent Heart Failure Hospitalizations and Cardiovascular Death in Patients with Heart Failure with Mid-range or Preserved Ejection Fraction [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Mar [cited 2026 Jan 11]. Report No.: NCT04727073. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04727073"},{"issue":"9","key":"10609_CR35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","volume":"11","author":"BA Borlaug","year":"2014","unstructured":"Borlaug BA (2014) The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 11(9):507\u2013515. https:\/\/doi.org\/10.1038\/nrcardio.2014.83PubMed PMID: 24958077","journal-title":"Nat Rev Cardiol"},{"issue":"10437","key":"10609_CR36","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(","volume":"403","author":"J Butler","year":"2024","unstructured":"Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstr\u00f8m SZ, Davies MJ et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet Lond Engl 403(10437):1635\u20131648. https:\/\/doi.org\/10.1016\/S0140-6736(24)00469-0 PubMed PMID: 38599221; PubMed Central PMCID: PMC11317105","journal-title":"Lancet Lond Engl"},{"issue":"10456","key":"10609_CR37","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/S0140-6736","volume":"404","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ et al (2024) Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet Lond Engl 404(10456):949\u2013961. https:\/\/doi.org\/10.1016\/S0140-6736(24)01643-X PubMed PMID: 39222642","journal-title":"Lancet Lond Engl"},{"key":"10609_CR38","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR, D\u2019Alessio D, Drucker DJ, Flatt PR et al (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010PubMed PMID: 31767182; PubMed Central PMCID: PMC6812410","journal-title":"Mol Metab"},{"issue":"6","key":"10609_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02","volume":"31","author":"RJ Samms","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW (2020) How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab TEM 31(6):410\u2013421. https:\/\/doi.org\/10.1016\/j.tem.2020.02.006 PubMed PMID: 32396843","journal-title":"Trends Endocrinol Metab TEM"},{"issue":"12","key":"10609_CR40","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.2337\/db11-0979","volume":"60","author":"M Christensen","year":"2011","unstructured":"Christensen M, Vedtofte L, Holst JJ, Vilsb\u00f8ll T, Knop FK (2011) Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60(12):3103\u20133109. https:\/\/doi.org\/10.2337\/db11-0979PubMed PMID: 21984584; PubMed Central PMCID: PMC3219957","journal-title":"Diabetes"},{"issue":"6","key":"10609_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK et al (2021) Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 385(6):503\u2013515 doi:10.1056\/NEJMoa2107519 PubMed PMID: 34170647","journal-title":"N Engl J Med"},{"issue":"17","key":"10609_CR42","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","volume":"84","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, Ostrominski JW, Wang X, Shah SJ, Borlaug BA, Butler J et al (2024) Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure. J Am Coll Cardiol 84(17):1587\u20131602 .021 PubMed PMID: 39217567","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10609_CR43","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","volume":"85","author":"CM Kramer","year":"2025","unstructured":"Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V et al (2025) Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. J Am Coll Cardiol 85(7):699\u2013706 .001 PubMed PMID: 39566869","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10609_CR44","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"Digitalis Investigation Group","year":"1997","unstructured":"Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336(8):525\u2013533. 101056\/NEJM199702203360801 PubMed PMID: 9036306","journal-title":"N Engl J Med"},{"issue":"5","key":"10609_CR45","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1093\/eurjhf\/hft010","volume":"15","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JGF et al (2013) Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 15(5):551\u2013559. https:\/\/doi.org\/10.1093\/eurjhf\/hft010PubMed PMID: 23355060; PubMed Central PMCID: PMC3707428","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10609_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","volume":"27","author":"A Ahmed","year":"2006","unstructured":"Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS et al (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27(2):178\u2013186. https:\/\/doi.org\/10.1093\/eurheartj\/ehi687PubMed PMID: 16339157; PubMed Central PMCID: PMC2685167","journal-title":"Eur Heart J"},{"issue":"12","key":"10609_CR47","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2415471","volume":"393","author":"U Bavendiek","year":"2025","unstructured":"Bavendiek U, Gro\u00dfhennig A, Schwab J, Berliner D, Rieth A, Maier LS et al (2025) Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 393(12):1155\u20131165 doi:10.1056\/NEJMoa2415471 PubMed PMID: 40879434","journal-title":"N Engl J Med"},{"issue":"20","key":"10609_CR48","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J et al (2020) Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 382(20):1883\u20131893 doi:10.1056\/NEJMoa1915928 PubMed PMID: 32222134","journal-title":"N Engl J Med"},{"issue":"10510","key":"10609_CR49","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736","volume":"406","author":"J Butler","year":"2025","unstructured":"Butler J, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M et al (2025) Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 406(10510):1341\u20131350. https:\/\/doi.org\/10.1016\/S0140-6736(25)01665-4 PubMed PMID: 40897189","journal-title":"Lancet"},{"issue":"10510","key":"10609_CR50","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0140-6736","volume":"406","author":"F Zannad","year":"2025","unstructured":"Zannad F, O\u2019Connor CM, Butler J, McMullan CJ, Anstrom KJ, Barash I et al (2025) Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials. Lancet 406(10510):1351\u20131362. https:\/\/doi.org\/10.1016\/S0140-6736(25)01682-4 PubMed PMID: 40897188","journal-title":"Lancet"},{"issue":"2","key":"10609_CR51","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","volume":"384","author":"JR Teerlink","year":"2021","unstructured":"Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD et al (2021) Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med 384(2):105\u2013116 doi:10.1056\/NEJMoa2025797 PubMed PMID: 33185990","journal-title":"N Engl J Med"},{"issue":"1","key":"10609_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/jamacardio.","volume":"7","author":"GM Felker","year":"2022","unstructured":"Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M et al (2022) Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. JAMA Cardiol 7(1):26\u201334. https:\/\/doi.org\/10.1001\/jamacardio.2021.4027 PubMed PMID: 34643642; PubMed Central PMCID: PMC8515258\u00a0","journal-title":"JAMA Cardiol"},{"issue":"48","key":"10609_CR53","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1093\/eurheartj\/ehac293","volume":"43","author":"M Metra","year":"2022","unstructured":"Metra M, Pagnesi M, Claggett BL, D\u00edaz R, Felker GM, McMurray JJV et al (2022) Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. Eur Heart J 43(48):5006\u20135016. https:\/\/doi.org\/10.1093\/eurheartj\/ehac293PubMed PMID: 35675469; PubMed Central PMCID: PMC9769958","journal-title":"Eur Heart J"},{"key":"10609_CR54","unstructured":"Multi-Center CA Double-Blind, Randomized, Placebo-Controlled Trial to Assess Efficacy and Safety of Omecamtiv Mecarbil in Patients With Symptomatic Heart Failure With Severely Reduced Ejection Fraction (COMET-HF) [Clinical trial registration] [Internet]. clinicaltrials.gov; 2025 Dec [cited 2025 Dec 14]. Report No.: NCT06736574. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06736574"},{"issue":"10369","key":"10609_CR55","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/S0140-6736(","volume":"400","author":"PR Kalra","year":"2022","unstructured":"Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB et al (2022) Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet Lond Engl 400(10369):2199\u20132209. https:\/\/doi.org\/10.1016\/S0140-6736(22)02083-9 PubMed PMID: 36347265","journal-title":"Lancet Lond Engl"},{"issue":"10266","key":"10609_CR56","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(","volume":"396","author":"P Ponikowski","year":"2020","unstructured":"Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J et al (2020) Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet 396(10266):1895\u20131904. https:\/\/doi.org\/10.1016\/S0140-6736(20)32339-4 PubMed PMID: 33197395","journal-title":"Lancet"},{"issue":"11","key":"10609_CR57","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","volume":"389","author":"RJ Mentz","year":"2023","unstructured":"Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA et al (2023) Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med 389(11):975\u2013986. 101056\/NEJMoa2304968 PubMed PMID: 37632463","journal-title":"N Engl J Med"},{"issue":"22","key":"10609_CR58","first-page":"2109","volume":"389","author":"SD Anker","year":"2023","unstructured":"Anker SD, Filippatos G, Anker MS (2023) Ferric Carboxymaltose in Heart Failure with Iron Deficiency. N Engl J Med 389(22):2109. 101056\/NEJMc2311874 PubMed PMID: 38048198","journal-title":"N Engl J Med"},{"issue":"22","key":"10609_CR59","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1001\/jama.2025.3833","volume":"333","author":"SD Anker","year":"2025","unstructured":"Anker SD, Friede T, Butler J, Talha KM, Placzek M, Diek M et al (2025) Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency: The FAIR-HF2 DZHK05 Randomized Clinical Trial. JAMA 333(22):1965\u20131976. https:\/\/doi.org\/10.1001\/jama.2025.3833","journal-title":"JAMA"},{"issue":"37","key":"10609_CR60","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","volume":"45","author":"S von Haehling","year":"2024","unstructured":"von Haehling S, Doehner W, Evertz R, Garfias-Veitl T, Derad C, Diek M et al (2024) Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial. Eur Heart J 45(37):3789\u20133800. https:\/\/doi.org\/10.1093\/eurheartj\/ehae479PubMed PMID: 39185895; PubMed Central PMCID: PMC11452748","journal-title":"Eur Heart J"},{"issue":"1","key":"10609_CR61","first-page":"41","volume":"24","author":"K Keramida","year":"2020","unstructured":"Keramida K, Filippatos G (2020) Heart failure guidelines implementation: Lifting barriers using registries and networks. Anatol J Cardiol 24(1):41\u201342 doi:10.14744\/AnatolJCardiol.2020.62747 PubMed PMID: 32628142; PubMed Central PMCID: PMC7414813","journal-title":"Anatol J Cardiol"},{"issue":"12","key":"10609_CR62","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/ejhf.3445","volume":"26","author":"LH Lund","year":"2024","unstructured":"Lund LH, Crespo-Leiro MG, Laroche C, Zaliaduonyte D, Saad AM, Fonseca C et al (2024) Heart failure in Europe: Guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction - the ESC EORP Heart Failure III Registry. Eur J Heart Fail 26(12):2487\u20132501. https:\/\/doi.org\/10.1002\/ejhf.3445PubMed PMID: 39257278; PubMed Central PMCID: PMC11683873","journal-title":"Eur J Heart Fail"},{"key":"10609_CR63","doi-asserted-by":"publisher","unstructured":"Seferovi\u0107 PM, Polovina M, Krej\u010di J, Merkely B, Tokmakova M, Huelssmann M et al (2025 Sep) Contemporary implementation of guideline-directed medical and device therapies in heart failure: Insights from the Central\/Eastern Europe Quality of Care Centres Survey. Eur J Heart Fail 24. https:\/\/doi.org\/10.1002\/ejhf.70031PubMed PMID: 40993994","DOI":"10.1002\/ejhf.70031"},{"key":"10609_CR64","doi-asserted-by":"publisher","unstructured":"Malgie J, Wilde MI, Koudstaal S, Denham R, da Fonseca CA, Swart HP et al (2025 Aug) Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF. Eur J Heart Fail 14. https:\/\/doi.org\/10.1002\/ejhf.70006PubMed PMID: 40808542","DOI":"10.1002\/ejhf.70006"},{"issue":"15","key":"10609_CR65","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.jacc.2017.08.010","volume":"70","author":"MM Givertz","year":"2017","unstructured":"Givertz MM, Stevenson LW, Costanzo MR, Bourge RC, Bauman JG, Ginn G et al (2017) Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. JACC 70(15):1875\u20131886. https:\/\/doi.org\/10.1016\/j.jacc.2017.08.010","journal-title":"JACC"},{"issue":"10394","key":"10609_CR66","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736","volume":"401","author":"JJ Brugts","year":"2023","unstructured":"Brugts JJ, Radhoe SP, Clephas PRD, Aydin D, van Gent MWF, Szymanski MK et al (2023) Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet Lond Engl 401(10394):2113\u20132123. https:\/\/doi.org\/10.1016\/S0140-6736(23)00923-6 PubMed PMID: 37220768","journal-title":"Lancet Lond Engl"},{"issue":"10","key":"10609_CR67","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/ejhf.3687","volume":"27","author":"CJ Kapelios","year":"2025","unstructured":"Kapelios CJ, Liori S, Bonios M, Abraham WT, Filippatos G (2025) Effect of pulmonary artery pressure-guided management on outcomes of patients with heart failure outside clinical trials: A systematic review and meta-analysis of real-world evidence with the CardioMEMS Heart Failure System. Eur J Heart Fail 27(10):1857\u20131865. https:\/\/doi.org\/10.1002\/ejhf.3687PubMed PMID: 40360446; PubMed Central PMCID: PMC12575415","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10609_CR68","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/j.jchf.2024.05.017","volume":"12","author":"JL Guichard","year":"2024","unstructured":"Guichard JL, Bonno EL, Nassif ME, Khumri TM, Miranda D, Jonsson O et al (2024) Seated Pulmonary Artery Pressure Monitoring in Patients With Heart Failure: Results of the PROACTIVE-HF Trial. JACC Heart Fail 12(11):1879\u20131893. https:\/\/doi.org\/10.1016\/j.jchf.2024.05.017PubMed PMID: 39152983","journal-title":"JACC Heart Fail"},{"issue":"24","key":"10609_CR69","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM et al (2018) Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379(24):2307\u20132318. 101056\/NEJMoa1806640 PubMed PMID: 30280640","journal-title":"N Engl J Med"},{"issue":"19","key":"10609_CR70","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa2314328","volume":"391","author":"SD Anker","year":"2024","unstructured":"Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M et al (2024) Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation. N Engl J Med 391(19):1799\u20131809. https:\/\/doi.org\/10.1056\/NEJMoa2314328","journal-title":"N Engl J Med"},{"issue":"10330","key":"10609_CR71","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/S0140-6736","volume":"399","author":"SJ Shah","year":"2022","unstructured":"Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS et al (2022) Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial. Lancet Lond Engl 399(10330):1130\u20131140. https:\/\/doi.org\/10.1016\/S0140-6736(22)00016-2 PubMed PMID: 35120593","journal-title":"Lancet Lond Engl"},{"issue":"4","key":"10609_CR72","doi-asserted-by":"publisher","first-page":"e008362","DOI":"10.1161\/CIRCHEARTFAILURE.121.008362","volume":"15","author":"W Sun","year":"2022","unstructured":"Sun W, Zou H, Yong Y, Liu B, Zhang H, Lu J et al (2022) The RAISE Trial: A Novel Device and First-in-Man Trial. Circ Heart Fail 15(4):e008362. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.121.008362PubMed PMID: 35378984","journal-title":"Circ Heart Fail"},{"key":"10609_CR73","unstructured":"Feasibility of a No-Implant Approach to Interatrial Shunts Preclinical and Early Clinical Studies - PubMed [Internet]. [cited 2025 Nov 29]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37288335\/"},{"issue":"5","key":"10609_CR74","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1002\/ejhf.2119","volume":"23","author":"C Paitazoglou","year":"2021","unstructured":"Paitazoglou C, Bergmann MW, \u00d6zdemir R, Pfister R, Bartunek J, Kilic T et al (2021) One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study. Eur J Heart Fail 23(5):800\u2013810. https:\/\/doi.org\/10.1002\/ejhf.2119PubMed PMID: 33555114","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"10609_CR75","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1016\/j.jcin.2018.07.001","volume":"11","author":"J Rod\u00e9s-Cabau","year":"2018","unstructured":"Rod\u00e9s-Cabau J, Bernier M, Amat-Santos IJ, Ben Gal T, Nombela-Franco L, Garc\u00eda D, Blanco B et al (2018) Interatrial Shunting for Heart Failure: Early and Late Results From the First-in-Human Experience With the V-Wave System. JACC Cardiovasc Interv 11(22):2300\u20132310. https:\/\/doi.org\/10.1016\/j.jcin.2018.07.001PubMed PMID: 30391390","journal-title":"JACC Cardiovasc Interv"},{"issue":"24","key":"10609_CR76","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.124.070870","volume":"150","author":"GW Stone","year":"2024","unstructured":"Stone GW, Lindenfeld J, Rod\u00e9s-Cabau J, Anker SD, Zile MR, Kar S et al (2024) Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial. Circulation 150(24):1931\u20131943. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.070870PubMed PMID: 39308371; PubMed Central PMCID: PMC11627316","journal-title":"Circulation"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10609-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10609-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10609-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:50:02Z","timestamp":1781639402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10609-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10609"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10609-3","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"13 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CJK reports honoraria from Abbott, AstraZeneca, Bayer. GS reports grants and personal fees from CSL Vifor, Boehringer Ingelheim, AstraZeneca, Servier, Novartis, Cytokinetics, Pharmacosmos, Medtronic, Bayer, and personal fees from Roche, Abbott, Edwards Lifesciences, TEVA, Menarini, INTAS, GETZ, Laboratori Guidotti, Lupin, and grants from Boston Scientific, Merck, all outside the submitted work. GF reports lecture fees and \/or advisory and \/or trial committee membership by Bayer, Boehringer Ingelheim, Servier, Novartis, Impulse Dynamics, Vifor, Medtronic, MSD, Cardior, Novo Nordisk and Research Grants from the European Union.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}}],"article-number":"34"}}